Screening methods for identifying Sp35 antagonists
AssigneeBiogen MA Inc.
InventorsSha Mi, R. Blake Pepinsky, John McCoy
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist.
Claims20
A method of identifying an Sp35 antagonist capable of promoting oligodendrocyte-mediated myelination comprising contacting a co-culture of neurons and oligodendrocytes with a compound that binds to Sp35 or to a polynucleotide that encodes Sp35 and measuring myelination, wherein increased myelination compared to a control co-culture indicates the compound is an Sp35 antagonist capable of promoting oligodendrocyte-mediated myelination.
A method of identifying an Sp35 antagonist capable of promoting oligodendrocyte differentiation comprising contacting a culture of progenitor oligodendrocytes with a compound that binds to Sp35 or to a polynucleotide that encodes Sp35 and quantitating the number of pre-myelinating or mature oligodendrocytes, wherein increased pre-myelinating or mature oligodendrocytes compared to a control culture indicates the compound is an Sp35 antagonist capable of promoting oligodendrocyte differentiation.
A method of identifying an Sp35 antagonist capable of promoting oligodendrocyte survival comprising contacting a culture of mature oligodendrocytes with a compound that binds to Sp35 or to a polynucleotide that encodes Sp35 and measuring oligodendrocyte survival, wherein increased oligodendrocyte survival compared to a control culture indicates the compound is an Sp35 antagonist capable of promoting oligodendrocyte survival.
Dependencies are inferred from the claim text.